ONWARD® MEDICAL ANNOUNCES PRESENTATION AT BIOCAPITAL EUROPE
07 Février 2024 - 9:55PM
UK Regulatory
EINDHOVEN, the Netherlands, Feb. 07, 2024 (GLOBE
NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical
technology company creating innovative spinal cord stimulation
therapies to restore movement, function, and independence in people
with spinal cord injury (SCI), today announces its participation in
BioCapital Europe in Amsterdam on February 8, 2024. The event, one
of Europe’s leading life sciences investor conferences, is
organized by life sciences venture capital fund EQT Life Sciences,
an investor in ONWARD Medical.
ONWARD Medical CEO Dave Marver will
present and participate in 1:1 and group meetings with investors
during the conference. During his engagements, he will also discuss
the Company’s leadership in innovative health solutions, including
the use of ONWARD ARC-IM® Therapy paired with brain-computer
interface (BCI) technology.
*All ONWARD
Medical devices and therapies, including but not limited
to ARC-IM®, ARC-EX®, and ARC
Therapy™, alone or in combination with a
brain-computer interface (BCI), are investigational and not
available for commercial use.
About ONWARD
Medical
ONWARD Medical is a medical technology
company creating therapies to restore movement, function, and
independence in people with spinal cord injury (SCI) and movement
disabilities. Building on more than a decade of science and
preclinical research conducted at leading neuroscience
laboratories, the Company has received nine Breakthrough Device
Designations from the US Food and Drug Administration for its ARC
Therapy™ platform.
ONWARD® ARC Therapy, which can be
delivered by external ARC-EX or implantable ARC-IM systems, is
designed to deliver targeted, programmed spinal cord stimulation.
Positive results were presented in 2023 from the Company’s pivotal
study, called Up-LIFT, evaluating the ability for transcutaneous
ARC Therapy to improve upper extremity strength and function. The
Company is now preparing regulatory approval submissions for ARC-EX
for the US and Europe. In parallel, the Company is conducting
studies with its implantable ARC-IM platform, which demonstrated
positive interim clinical outcomes for improved blood pressure
regulation, a component of hemodynamic instability, following SCI.
Other ongoing studies include combination use of ARC-IM with a
brain-computer interface (BCI) to address multiple symptoms of
SCI.
Headquartered in Eindhoven, the
Netherlands, ONWARD Medical has a Science and Engineering Center in
Lausanne, Switzerland and a US office in Boston, Massachusetts. The
Company also has an academic partnership with .NeuroRestore, a
collaboration between the Swiss Federal Institute of Technology
(EPFL), and Lausanne University Hospital (CHUV).
ONWARD Medical is listed on Euronext
Brussels and Amsterdam (ticker: ONWD).
For more information, visit ONWD.com,
and connect with us on LinkedIn and YouTube.
For Media Enquiries:
Aditi Roy, VP
Communications
media@onwd.com
For Investor Enquiries:
Khaled Bahi, Interim CFO
investors@onwd.com
Disclaimer
Certain statements, beliefs, and
opinions in this press release are forward-looking, which reflect
the Company’s or, as appropriate, the Company directors’ current
expectations and projections about future events. By their nature,
forward-looking statements involve several risks, uncertainties,
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties, and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition, and technology, can
cause actual events, performance, or results to differ
significantly from any anticipated development. Forward-looking
statements contained in this press release regarding past trends or
activities should not be taken as a representation that such trends
or activities will continue in the future. As a result, the Company
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions, or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release. All ONWARD Medical devices and therapies referenced
here, including but not limited to ARC-IM, ARC-EX, and ARC Therapy,
are investigational and not available for commercial use.
Onward Opportunities (LSE:ONWD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Onward Opportunities (LSE:ONWD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024